Evidence map›Paper›PMID 38862493›Full record

ArticleBlood cancer journal2024

Performance of newer myeloma staging systems in a contemporary, large patient cohort.

Ghulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kumar, S Vincent Rajkumar, Rafael Fonseca, Nadine H Abdallah, Gregory S Calip, Xiaoyan Wang, Christina M Parrinello, Douglas Sborov

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ghulam Rehman MohyuddinHuntsman Cancer Institute, University of Utah, Salt lake, UT, USA. g.mohyuddin@hci.utah.edu.ORCID 0000-0001-6464-783X
Samuel M RubinsteinLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Shaji KumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5392-9284
S Vincent RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5862-1833
Rafael FonsecaDivision of Hematology, Mayo Clinic, Phoenix, AZ, USA.ORCID 0000-0002-5938-3769
Nadine H AbdallahDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9195-1589
Gregory S CalipTitus Family Department of Clinical Pharmacy, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-7744-3518
Xiaoyan WangFlatiron Health, New York, NY, USA.
Christina M ParrinelloPine Mountain Consulting, Larkspur, CA, USA.
Douglas SborovHuntsman Cancer Institute, University of Utah, Salt lake, UT, USA.

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Yi Lin · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaNeoplasm StagingAdultAgedAged, 80 and overCohort StudiesFemaleHumansMaleMiddle Aged

Identifiers

PMID38862493
PMCPMC11166956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.